ABUS - Latest News

Arbutus Biopharma Corp (ABUS), operates in Healthcare / Biotechnology, trades on NASDAQ.

Market capitalization stands near $827.7M. Trailing twelve-month P/E ratio is 5.41. Beta to the broader market is 0.62.

The article list below shows the most recent ABUS headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent ABUS Headlines

Arbutus Biopharma: $230M Buyback And Moderna Cash De-Risk The Path To A Potential HBV Cure

seekingalpha.com - Oct 8, 2026

Arbutus Biopharma is rated Buy, leveraging a $179. 1M Moderna settlement and a 46M share buyback to enhance per-share value.

Arbutus Biopharma (NASDAQ:ABUS) Stock Price Up 5.3% – Here’s What Happened

defenseworld.net - Oct 2, 2026

Arbutus Biopharma Corporation (NASDAQ: ABUS - Get Free Report) shot up 5. 3% during mid-day trading on Wednesday.

Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer

globenewswire.com - Oct 1, 2026

WARMINSTER, Pa. , Oct.

Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer

globenewswire.com - Sep 30, 2026

WARMINSTER, Pa. , Sept.

Connor Clark & Lunn Investment Management Ltd. Buys Shares of 130,023 Arbutus Biopharma Corporation $ABUS

defenseworld.net - Sep 1, 2026

Connor Clark and Lunn Investment Management Ltd. purchased a new position in shares of Arbutus Biopharma Corporation (NASDAQ: ABUS) in the second qua

How News Affects ABUS Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track ABUS's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.

Frequently asked ABUS news questions

What is the latest ABUS news headline?

The most recent ABUS headline (Oct 8, 2026) is "Arbutus Biopharma: $230M Buyback And Moderna Cash De-Risk The Path To A Potential HBV Cure". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.

How fresh is the ABUS news on this page?

News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.

What ABUS news moves options pricing?

Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.

How can I track unusual ABUS options activity related to news?

Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.